Dimerix Limited (ASX: DXB), is a clinical stage, biotechnology company that focusses on the development of new therapeutic treatments using its proprietary drug discovery platform, Receptor-Heteromer Investigation Technology (HIT).
We have sent an e-mail with a confirmation code to . In order to complete the sign-up process, please submit the code. If you do not receive a confirmation e-mail, please check your spam folder. Also, please verify that you entered a valid e-mail address in our sign-up form.